Lipid-Lowering Agents - Sweden

Sweden

The Lipid-Lowering Agents market in Sweden is anticipated to witness a substantial growth in revenue, projected to reach US$25.95m in 2024.
This market is expected to demonstrate an impressive annual growth rate (CAGR 2024-2028) of 0.00%, leading to a significant increase in market volume to US$25.95m by 2028.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$4,427.00m in 2024.
In Sweden, there is a growing trend towards the use of innovative lipid-lowering agents to address the high prevalence of cardiovascular disease in the population.

Key regions: Italy, Japan, France, Brazil, Australia

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Sweden has been growing steadily in recent years.

Customer preferences: Swedish customers are increasingly aware of the importance of maintaining healthy cholesterol levels, which has led to a growing demand for Lipid-Lowering Agents. Additionally, the aging population in Sweden has contributed to the increased demand for these drugs.

Trends in the market: The Lipid-Lowering Agents market in Sweden is dominated by statins, which are the most commonly prescribed drugs for lowering cholesterol levels. However, there has been a growing trend towards the use of PCSK9 inhibitors, which are a newer class of drugs that are more effective at lowering cholesterol levels than statins. This trend is expected to continue in the coming years as more patients switch to PCSK9 inhibitors.

Local special circumstances: The Swedish government heavily regulates the pharmaceutical industry, which has led to lower drug prices compared to other countries. This has made Lipid-Lowering Agents more affordable for Swedish patients, which has contributed to the growing demand for these drugs.

Underlying macroeconomic factors: Sweden has a strong healthcare system that provides universal coverage to all citizens. This has led to a high level of access to healthcare services, including Lipid-Lowering Agents. Additionally, the Swedish economy has been growing steadily in recent years, which has led to an increase in disposable income for many Swedish citizens. This has made it easier for patients to afford Lipid-Lowering Agents, which has contributed to the growing demand for these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.